DNTH vs JBIO
DNTH: Dianthus Therapeutics is a clinical-stage biopharmaceutical company developing targeted complement-pathway inhibitors to treat severe autoimmune and inflammatory diseases. JBIO: Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA nephropathy and rheumatoid arthritis.
Side-by-side fundamentals
| Metric | DNTH | JBIO | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $102.76 | $19.85 | |
| Market cap as of 2026-07-23 | $5.7B | $1.2B | |
| PEG as of 2026-07-23 | -0.59 | n/a | |
| Net margin as of 2026-07-23 | -12998.5% | n/a | |
| Operating margin as of 2026-07-23 | -14318.0% | n/a | |
| ROE as of 2026-07-23 | -27.3% | -51.3% | DNTH higher |
| ROA as of 2026-07-23 | -25.9% | -47.3% | DNTH higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -79.5% | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-07-23 | 1.75 | 1.42 | |
| 1-year return as of 2026-07-22 close | +409.7% | +136.2% | DNTH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.